D-0698-2018 Class III Terminated

Recalled by InvaGen Pharmaceuticals, Inc. — Central Islip, NY

FDA drug recall D-0698-2018 was initiated by InvaGen Pharmaceuticals, Inc. on Mar 5, 2018 and is designated Class III. Reason for recall: Failed impurities/degradation specifications: Failure to water content and impurity The recall status is terminated (terminated Jan 20, 2021). Affected quantity: 3222 vials.

Recall Details

Product Type
Drugs
Report Date
Apr 18, 2018
Initiation Date
Mar 5, 2018
Termination Date
Jan 20, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3222 vials

Product Description

Decitabine for Injection, 50mg per vial, Rx only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-285-37

Reason for Recall

Failed impurities/degradation specifications: Failure to water content and impurity

Distribution Pattern

U.S.A. nationwide

Code Information

Lot #: GE70493, GE70502, GE70512, Exp 8/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0698-2018
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0698-2018. Report a data issue: hello@regdatalab.com.